Not recruiting
Plasma cell myeloma refractory
Not recruitingStudy Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
Registered drugNo placebo
Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
Registered drugNo placebo
- Disease:Plasma cell myeloma refractory
- Substances:BortezomibDaratumumab+5
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Bortezomib



